anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Evidence suggests that eye movements have potential as a tool for detecting glaucomatous visual field defects. This study evaluated the influence of sampling frequency on eye movement parameters in detecting glaucomatous visual field defects during a free-viewing task.
METHODS: We investigated eye movements in two sets of experiments: (a) young adults with and without simulated visual field defects and (b) glaucoma patients and age-matched controls. In Experiment 1, we recruited 30 healthy volunteers. Among these, 10 performed the task with a gaze-contingent superior arcuate (SARC) scotoma, 10 performed the task with a gaze-contingent biarcuate (BARC) scotoma and 10 performed the task without a simulated scotoma (NoSim). The experimental task involved participants freely exploring 100 images, each for 4 s. Eye movements were recorded using the LiveTrack Lightning eye-tracker (500 Hz). In Experiment 2, we recruited 20 glaucoma patients and 16 age-matched controls. All participants underwent similar experimental tasks as in Experiment 1, except only 37 images were shown for exploration. To analyse the effect of sampling frequency, data were downsampled to 250, 120 and 60 Hz. Eye movement parameters, such as the number of fixations, fixation duration, saccadic amplitude and bivariate contour ellipse area (BCEA), were computed across various sampling frequencies.
RESULTS: Two-way ANOVA revealed no significant effects of sampling frequency on fixation duration (simulation, p = 0.37; glaucoma patients, p = 0.95) and BCEA (simulation, p = 0.84; glaucoma patients: p = 0.91). BCEA showed good distinguishability in differentiating groups across different sampling frequencies, whereas fixation duration failed to distinguish between glaucoma patients and controls. Number of fixations and saccade amplitude showed variations with sampling frequency in both simulations and glaucoma patients.
CONCLUSION: In both simulations and glaucoma patients, BCEA consistently differentiated them from controls across various sampling frequencies.
PURPOSE:To obtain an antimicrobial agent useful as a preservative for food, cosmetic, etc. in high yield in one stage, by adsorbing an extract of a licorice with an organic solvent in a basic anion exchange resin or porous resin, and eluting the adsorbed extract with an organic solvent or aqueous alkali. CONSTITUTION:A licorice or a residue after extracting a sweetening component with an aqueous solvent is extracted with an organic solvent, and the resultant extract is adsorbed in a basic anion exchange resin, e.g. styrene based porous or acrylic amine type resin or a porous resin, e.g. styrene or acrylic resin. The adsorbed extract is then eluted with an organic solvent, e.g. CH3OH or C2H5OH, or aqueous alkali, e.g. 0.1N aqueous solution of NaOH, to give the aimed antimicrobial agent. The organic solvent for extraction is preferably a halogenated hydrocarbon or aromatic hydrocarbon from the viewpoint of the color and smell of the resultant antimicrobial agent. The antimicrobial activity can be increased to 4-5 times based on the equal amount as compared with that of the crude extract, and colored and malodorous materials can be reduced.
The present invention provides a series of novel bifunctional molecules based on viologen linked acridine, bisacridine and bisacridinium salts of the general formula 1 (1a, 1b, 1c and 1d) and or pharmaceutically acceptable derivatives thereof, which can be used as phototherapeutic and catalytic photoactivated DNA cleaving agents. These molecules are very stable and exhibit high solubility in buffer at physiological conditions. They undergo strong binding with DNA through intercalation and groove binding interactions and show remarkably high affinity for poly(dA).poly(dT) sequences. Upon photoactivation, they cleave DNA catalytically and selectively at guanine (G) sites in duplex DNA exclusively through cosensitization mechanism with a preference for 5′-G over 3′-G. They induce unusally high specificity of cleavage at G site of the AG two base bulge sequences. Accordingly, the viologen linked acridine based molecules described herein are extremely useful as probes for DNA structures and catalytic photoactivated DNA cleaving agents in biological applications.
This open label, single-arm, Phase 2 study aims to evaluate the efficacy and safety of Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture. Anti-FcRL5 chimeric antigen receptor (CAR) modified T cells. Prior to Anti-FcRL5 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide. After infusion, the investigators will observe the characteristics of dose limited toxicity (DLT), and determine the maximum tolerable agent MTD and rp2d were confirmed. To provide basis for the dosage and treatment plan of cell products in follow-up clinical trials.
The present invention relates to the identification and application of a new member Dok5 of the signaling pathway BDNF, NT-3 of the neurotrophic factors. The present invention clones the gene dok5 of a human, which encodes a cytoplasm signal protein. It is proved by yeast two-hybrid experiments, pulldown experiments and co-immunoprecipitation experiments that dok5 can bind the NPQY motif in the intracellular region of TrkB and TrkC which are the receptor of BDNF and NT-3 in a way depending on receptor phosphorylations. The fluorescence experiments of cells show that dok5 is co-localized with receptor TrkB and TrkC in cell PC12. And the detection of the signaling pathway MAPK shows that dok5 can effectively enhance the activation level and extend the activity time of the signaling pathway MAPK induced by BNDF and NT-3. As a medicine treating various nervous system diseases, BDNF and NT-3 have entered clinical experiments. Dok5 is able to bind TrkB and TrkC which are the receptor of BDNF and NT-3 and also can enhance effectively the activation of signaling pathway BDNF, NT-3, so as to provide a new target for the treatment of various nervous system diseases and can be used to develop new medicines for nervous system diseases.
Gut microbiota composition and function has an important role in host physiology. In general, gut microbial diversity is positively correlated with health status. Recent evidence confirms the role of gut dysbiosis in cardiovascular disease. Americans consume 50% more salt than the amount recommended by the Dietary Guidelines and 130% more than recommended by the American Heart Association. Excess salt intake is considered a modifiable risk factor for cardiovascular disease. Changes in the gut microbiota composition followed by immune system activation is reported with high salt intake in animals. In particular, abundance of proinflammatory T helper 17 (Th17) cells increases with excess salt consumption. In contrast, T regulatory (Treg) cells oppose Th17 cell action and may aid in reducing inflammation associated with high salt intake, a hypothesis that has not yet been tested in humans. Only one preliminary study assessed changes in gut bacterial composition with high salt intake in humans, when only men were recruited. The study also found an increase in Th17 cell abundance. Thus, the objective of this study is to investigate the influence of high salt intake on the gut microbiota diversity and Th17 and Treg cell abundance in men and women.
Prior to surgery, an ultrasound-guided localization will be performed and albumin marked with Technetium 99m will be injected close to the tumor and in the subareolar area. During surgery, a specific probe will be used to locate the lesion and sentinel lymph node.
A automated system and associated method for storing medical items comprises a medication cabinet having at least one refrigerated drawer using a thermo-electric cooling (TEC) device and a non-refrigerated drawer. The drawer design is such that cooling gradients throughout the drawer are minimized. Faraday cages are provided about each drawer to support separate RFID readers to monitor the medical items in each drawer. The refrigerated drawer is insulated so that adjacent non-refrigerated drawers are not significantly affected by the temperature of the refrigerated drawer and they may exist at room temperature. An automatic RFID data detection system determines the temperature requirements of medical items in the refrigerated drawer and controls the TEC device to maintain the required temperature. A temperature logging system for the refrigerated drawer is provided. A separate RFID reader determines if a temperature-controlled item has been place in a non-refrigerated drawer and if so, an alert is provided.
Methods, systems, and computer-readable media are provided for an application messaging integration framework. An example method includes receiving a user input at a first clinical viewer via an integrated interface. The example method includes sending a message based on the input to a second clinical viewer via an application and messaging integrator. The application and messaging integrator is created to facilitate communication between the first and second clinical viewers. The example method includes updating information at the second clinical viewer based on the message. The example method includes displaying the updated information at the second clinical viewer via the integrated interface.
FIELD: biotechnology. SUBSTANCE: method involves immunization of animals with bacterial antigens introduced into lymphonodi and intramuscularly with solution of feracryl followed by drawing blood, separating immune serum forming an antigen-antibody complex and intravenous immunization with said complex. Time for preparation of horses producing tularemia diagnostic serum is reduced from 2.5-3 years to 2-3 months. Rabbits producing brucellosis agglutinating serum are prepared with inactivated antigens instead of live virulent cultures of brucellosis causative agents which rules out the necessity for strict observance of antiepidemic conditions. Sera prepared according to claimed method can be utilized for producing labelled gamma-globulins. EFFECT: higher efficiency.
Over the past 50 years, the incidence of diabetes has increased dramatically, while sleep duration in the US has decreased significantly. Epidemiological studies and small clinical trials suggest that these trends are causally related. In this study, our goal is to determine the mechanisms by which decreased sleep duration directly affects insulin sensitivity. The investigators will perform a clinical study in 20 healthy volunteers to determine whether 5 nights of sleep restriction decreases insulin sensitivity in the peripheral tissues (ie, skeletal muscle) or liver.

Peripheral insulin sensitivity will be measured by the hyperinsulinemic-euglycemic clamp, and hepatic insulin sensitivity will be quantified by measurement of hepatic glucose production, gluconeogenesis and glycogenolysis (using stable isotope tracer methods). Subjects will be randomized to an initial period of "normal sleep" or sleep restriction and will be admitted to the Clinical Research Center (CRC) for 9 days to undergo comprehensive metabolic studies and sleep assessments under the assigned sleep condition. After a 1-month washout period, subjects will be re-admitted to the CRC to undergo these same assessments under the opposite sleep condition.
BACKGROUND AND OBJECTIVE: Despite the constant improvement of coronary heart disease (CHD) diagnostics and treatment methods it remains one of the main causes of death in most countries around the world. And myocardial infarction with ST segment elevation on the electrocardiogram (STEMI) still is one of the most dangerous clinical variants of CHD. This study aims to develop an explainable machine learning model for in-hospital mortality (IHM) risk prediction in STEMI patients after myocardial revascularization by percutaneous coronary intervention (PCI).
METHODS: A single-center observational retrospective study was conducted, enrolling 4677 electronic medical records of patients with STEMI after PCI, which were analyzed using statistical analysis and machine learning methods. A pool of potential IHM predictors was identified, and prognostic models were developed and validated based on multivariate logistic regression, random forest, and stochastic gradient boosting methods at two stages of hospital treatment: during the initial physicians examination in the emergency department and immediately after PCI surgery. To explain the IHM prognosis, threshold values of IHM risk factors were determined using 3 grid search methods for optimal cut-off points, calculating centroids and SHapley Additive exPlanations (SHAP).
RESULTS: IHM prognostic models were developed using clinical and functional status data of STEMI patients during two stages of hospital treatment. The IHM prediction accuracy according to the first scenario was AUC = 0.85, and according to the second - AUC = 0.9. Predictors identified and validated in the models were converted into risk factors. Models whose parameters were risk factors demonstrated high forecast accuracy (AUC = 0.87), with the best model formed using the SHAP method.
CONCLUSIONS: For the forecast result interpretation risk factors obtained by categorizing continuous variables can be used by assessing the impact of the latter on the end point using the SHAP method.
Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
The first step of the study will be direct comparison of mirabegron (protocol A) vs. cold-induced (protocol B) BAT metabolic activation using 11C-acetate to measure BAT metabolic activity. The principle of this method is measurement of tissue fast disappearance of 11C, a marker of tissue 11CO2 production. This fast tissue 11C clearance thus gives an index of tissue oxidative metabolism. Ten healthy, non obese men will undergo two identical 5h procedures in which BAT metabolism will be stimulated with a β3-agonist (mirabegron 50mg) or using cold exposure, in random order. The investigator just received approval from Health Canada to use mirabegron as part of these metabolic investigations. In brief, baseline blood samples and indirect calorimetry will be performed between time -60 to -30 min followed by i.v. injection of 11C-acetate with 30 min dynamic PET/CT scanning at room temperature in both protocol A and B. Mirabegron will be administered orally at time 0 in protocol A whereas acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B. At time 210 min (i.e. Tmax of plasma mirabegron level or 90 min after the onset of cold exposure), i.v. injection of 11C-acetate will be repeated followed by 30 min dynamic PET/CT scanning. I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning to determine BAT net glucose uptake and a whole-body PET/CT scan to determine BAT volume of metabolic activity and organ-specific glucose partitioning.
The ability to identify the culprit carotid plaque represents a key goal in carotid artery imaging. Although an array of non-invasive imaging techniques can detect a wide spectrum of complementary high-risk characteristics, no single modality can reliably identify vulnerable plaques associated with future stroke development. Substantial histological data suggests that specific plaque components identify patients at high-risk for future ipsilateral stroke and cardiovascular events. This implies that investigators need to look beyond the traditional paradigm where the basis for carotid endarterectomy were formulated by an invasive imaging modality that provided no information on the arterial wall composition. Alternative imaging strategies are therefore required targeting not only in vivo carotid morphology but also plaque biology and disease activity. This is fundamental to optimal risk-stratification and appropriate selection of patients for high-risk vascular intervention. One new approach is to use non-invasive molecular imaging targeted at plaque biology using hybrid systems such as positron emission tomography-magnetic resonance imaging.
BACKGROUND: Clinical observational study demonstrated that hypertension is an independent risk factor for stroke. Furthermore, both hypertension and stroke exhibit genetic predispositions. However, the genetic relationship between hypertension and stroke in first-degree relatives remains unclear.
METHOD: The Genetic effects were validated using an across-Mendelian randomization (MR) approach. The Genome-Wide Association Study summary data used in this study were obtained from a publicly available platform. The primary MR effect employed was inverse-variance weighted (IVW), and the other analysis methods included MR-Egger, weighted median, simple mode, and weighted mode. Prior to MR analysis, tests for MR_PRESSO, pleiotropy, and heterogeneity were conducted.
RESULT: The presence of family history of hypertension significantly contributed to the genetic predisposition to various types of stroke, including ischemic stroke, subarachnoid hemorrhage, lacunar stroke, cardioembolic ischemic stroke, small vessel ischemic stroke, and large artery atherosclerosis-related ischemic stroke.
CONCLUSION: Briefly, hypertension in first-degree relatives has a genetic impact on the risk of stroke development. Shared genetic factors may exist between hypertension and stroke.
Ki67 proliferation index will be used to detect rapidly proliferating cells which means the percentage of positive Ki67 cells over 5 high power fields. It will be semiquantitatively graded as low, moderate, or high and correlated with histological staging.
The invention relates to products and compositions that may be beneficial in animal husbandry. Said products and compositions comprise microorganisms, such as bacteria, and probiotic bacteria in particular. Thus, provided herein are microbial strains, as well as selection criteria which will enable the skilled reader to find further strains useful in the present invention. The strains, as well as compositions comprising the same, may be administered to animals, farmed animals such as swine in particular. The administration may occur in the first days of life. By administration of the products or compositions of the inventions animal growth can. be promoted and animal weight can be increased. Infections may also be prevented or treated by said compounds or compositions.
Wrist based health devices, often with mobile connectivity, that continuously or near continuously track heart rate, blood pressure, temperature, activity and sleep are growing in everyday popularity and beginning to enter the sphere of clinical relevance. However, their accuracy and utility for clinical use is largely unstudied. As these consumer devices, some of which are FDA approved, become more commonplace, it is paramount to understand their function, know their limitations, and be able to interpret results appropriately before incorporating them into our clinical practice. The AHA/ACC 2017 guideline makes a 1A recommendation for clinical use of out of office BP measurements(1). This recommendation is based on evidence that out of office BP and frequent and longitudinal BP measurements are important in predicting cardiovascular risk and monitoring treatment efficacy(2-5). This trend towards consumer driven digital health monitoring and the new AHA/ACC guideline are essentially advancing a consumer based precision medicine strategy for diagnosis and monitoring of hypertension. As this becomes commonplace in our patient population, we need rigorous clinical study of wrist base BP monitoring to better understand its role patient care.
Subjects will receive a SC dose of MVA 2x10\^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
The aim of this study is to compare motor functions and quality of life of the children, and anxiety and depression levels of caregivers according to feeding type of children with cerebral palsy. Children will be divided into two groups: children with oral feeding and children with non-oral feeding, according to Functional Oral Intake Scale. Gross Motor Function Classification System will be used for classify children according to gross motor function, Gross Motor Function Measurement will be used for evaluate gross motor functions, and parent-reported Pediatric Quality of Life Inventory will be used for evaluate quality of life of children. To measure caregivers' anxiety and depression levels will be assessed by using Beck Depression Inventory and Beck Anxiety Inventory. Parametric or non-parametric tests will be applied according to the variables distribution. Through this analyses, determination of the difference between feeding type groups and other categorical and continuous variables will be decided.
Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. 

Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. In trials of tadalafil, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for tadalafil 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil 40 mg was 4% compared to 5% in placebo-treated patients. 

In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil 40 mg group and occurring more frequently than with placebo.
The invention relates to a compounding and preparation method for capsule used for preventing and curing diabetes. Raw material comprises gadol, dimorphantis, radix salviae miltiorrhizae, paeonol, corn silk, Atractylis ovata, radix astragali, flavonoids in hawthorn leaf, solomonseal, aconitum fischeri peichb, mulberry leaf and phlorhizin. A right amount of ethanol is added into raw material of gadol, dimorphantis, radix salviae miltiorrhizae, paeonol, corn silk, atractylis ovata, radix astragali, flavonoids in hawthorn leaf, solomonseal, aconitum fischeri peichb and mulberry, which are heated, abstracted, reclaimed, dried and milled. Then the gadol, dimorphantis, flavonoids in hawthorn leaf and phlorhizin with right amount are added, which are mixed, pelletized and encapsulated. The capsule can effectively prevent and cure acute and chronic diabetes and complication. Symptom of the diabetes can be conditioned to normal state if the capsule is taken for long time. The present invention pertains to pure Chinese traditional medicine product without side effect and dependence. The present invention is evident in curative effect, low in price, simple in preparation method, suitable for mass consumption and can be easily operated by the manufacturers.